• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Moderna's Small Base Could Surprise on the Upside

Prices have moved above the early January high giving us the simple definition of an uptrend.
By BRUCE KAMICH
Feb 14, 2019 | 01:17 PM EST
Stocks quotes in this article: MRNA

Biotechnology company Moderna Inc. (MRNA) was mentioned during Wednesday night's Lightning Round on Jim Cramer's Mad Money program. Cramer said, "This is a speculative one, but these guys are winners. Good call with this one." MRNA is a recent IPO so we do not have a lot of price history to work with be let's check on what we do have. A small map is better than no map.

In this daily bar chart of MRNA, below, we can see a small bottom pattern with a low in late December and a retest and higher low in late January. Prices have moved above the early January high giving us the simple definition of an uptrend. MRNA is trading above the rising 20-day moving average line (not enough activity to calculate a 50-day line yet). Trading volume is light but the daily On-Balance-Volume (OBV) line shows a rise and signals more aggressive buying. The Moving Average Convergence Divergence is above the zero line and bullish.

In this limited Point and Figure chart, below, we can see that a trade at $20.20 will be a positive development.

Bottom line strategy: if you are comfortable with a new issue then I would probe the long side of MRNA near $18 and risk a close below $16.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Technical Analysis | Biotechnology

More from Investing

To Be a Great Trader, Plan on Losing Money

James "Rev Shark" DePorre
Dec 14, 2019 10:00 AM EST

Losses are simply a function of the trading process and are not an indication of failure.

A Quiet Conclusion to a Dramatic and Contentious Issue

James "Rev Shark" DePorre
Dec 13, 2019 4:24 PM EST

This market has such a positive brew that has to make you at least a little apprehensive.

Facebook Investors Shouldn't Panic Over Reports the FTC Wants an Injunction

Eric Jhonsa
Dec 13, 2019 2:44 PM EST

Recent reports have heightened fears that the FTC will push for Facebook to be broken up. But any such effort is by no means guaranteed to succeed...and might not be a disaster for shareholders even if it did.

Currencies Will Eventually Matter for Crude Oil and Other Commodities

Carley Garner
Dec 13, 2019 2:00 PM EST

If the currency markets come back to life it will put oil back on the trading screens of speculators.

My Trade Idea for Oracle

Stephen Guilfoyle
Dec 13, 2019 12:30 PM EST

ORCL is competing for the business to business cloud, obviously a tough space.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:10 AM EST BOB LANG

    Banking a Big Winner in SRPT, Rolling Up

    Nov. 20 here on the CC, I mentioned buying some Ma...
  • 10:36 AM EST GARY BERMAN

    Fibocall: How High Can Crude Go?

    On crude: I am looking for higher, but please b...
  • 08:20 AM EST BOB LANG

    Webinar Time - Talkin' Calendars, Butterflys

    join me later today after the market close as we t...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2019 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login